Case Report

Acute Flaccid Tetraparesis after COVID-19 Infection: Think of the Thyroid

Sarah Ying Tse Tan, Jiaqing Xiong, Troy H Puar, Joan Khoo, Andy Jun-wei Wong, and Shui Boon Soh

Department of Endocrinology, Changi General Hospital, Singapore

Correspondence should be addressed to Sarah Ying Tse Tan; sarah.tan92@yahoo.com

Received 28 December 2021; Accepted 30 March 2022; Published 29 April 2022

Copyright © 2022 Sarah Ying Tse Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A previously well 32-year-old Chinese male presented with acute bilateral upper and lower limb paralysis upon waking, ten days after the onset of COVID-19 infection. Examination revealed areflexia over all four limbs, associated with reduced muscle strength, but no sensory or cranial nerve deficit. Initial concern was Guillain-Barre syndrome given the acute flaccid paralysis following COVID-19 infection. However, investigations revealed severe hypokalaemia (1.7 mmol/L) and primary hyperthyroidism. He was treated for thyrotoxic periodic paralysis (TPP) with β-blockers, antithyroid medications, and intravenous potassium chloride (KCl). Despite frequent monitoring of potassium, rebound hyperkalaemia occurred with prompt resolution of paralysis.

1. Introduction

This is the first case report of TPP occurring after COVID-19 infection, which presented with acute flaccid tetraparesis. COVID-19 infection is associated with multiple complications including neurological, endocrinological, and autoimmune diseases. TPP is an uncommon complication of Graves’ disease and may mimic other neurologic complications of COVID-19 infection such as demyelinating disorders. This emphasises the importance of assessing for metabolic disorders. In patients with severe hypokalaemia, a thyroid panel should be checked, bearing in mind the association between COVID-19 infection and Graves’ disease. Finally, the acute management of patients with TPP and severe hypokalaemia can be challenging, and judicious potassium replacement with frequent monitoring is imperative to avoid rebound hyperkalaemia.

2. Case Summary

A previously well 32-year-old Chinese male presented to the emergency department with acute weakness of bilateral upper and lower limbs. He slept well the night before, but was unable to walk or lift his lower limbs upon waking. Upper limb strength was also reduced bilaterally. He had no numbness, facial drooping, slurring of speech, blurring of vision, or incontinence. There was no preceding headache, neck pain, or trauma. He had been diagnosed with COVID-19 upper respiratory tract infection ten days ago, and his symptoms of fever, runny nose, cough, and sore throat had since resolved. However, he reported weight loss of 5 kg over the past few weeks. He took a carbohydrate-rich diet mainly consisting of rice, which he had taken the night before as well. He did not notice any neck pain or swelling, palpitations, or diarrhoea. He had no personal nor family history of neuromuscular disease, thyroid disease, or hypokalaemia and was not on any long-term medications or supplements.

On examination, he was afebrile but tachycardic (heart rate 116 beats per minute). Blood pressure was 127/73 mmHg and respiratory rate 16 breaths per minute. He was alert and conversant with clear speech. Tone was reduced in all four limbs, associated with absent biceps, triceps, supinator, knee, and ankle reflexes. There was profound weakness of his lower limbs and trunk (power 2/5...
both proximally and distally), with less severe weakness in his upper limbs (power 3/5 proximally, 4/5 distally). There was no sensory deficit. Cranial nerves were intact with preservation of respiratory, ocular, and bulbar muscular function. He had a small diffuse goitre that was nontender, with no bruit. Fine tremors were present in both the hands. There were no signs of thyroid eye disease or pretibial myxoedema.

There was initial concern for Guillain-Barre syndrome given his acute flaccid paralysis following COVID-19 infection. Other differentials included hypothycaemic or thyrotoxic periodic paralysis (TPP). Subsequent investigations (Table 1) revealed severe hypokalaemia (1.7 mmol/L) and primary hyperthyrotoxicosis (FT4 28.96 pmol/L; TSH < 0.004 mIU/L), establishing the diagnosis of thyrotoxic periodic paralysis. TSH receptor antibody was positive (2.4 U/L), consistent with Graves’ disease. Electrocardiogram showed sinus tachycardia but no u-waves (Figure 1). He was transferred to the high dependency unit, placed on telemetry monitoring, and initiated on intravenous (IV) potassium chloride (KCl) replacement. Despite receiving 56 mmol of KCl, his serum potassium level fell from 1.7 mmol/L to 1.6 mmol/L in the first four hours (prior to thyroid function test results). When primary hyperthyroidism was confirmed, he was initiated on oral propranolol 20 mg, carbimazole 20 mg, continued on IV KCl replacement, and serum potassium improved to 2.2 mmol/L. Potassium levels were checked frequently every four hours, and his subsequent potassium rose rapidly to 6.3 mmol/L. This was accompanied by prompt resolution of his paralysis, and muscle strength in all four limbs returned to normal. Potassium infusion was immediately stopped, and he was given IV Actrapid 10 u with 40 ml of 50% dextrose to correct hyperkalaemia. Serum potassium recovered to 4.6 mmol/L. Carbimazole 20 mg OM and propranolol 20 mg TDS were continued, and serum potassium levels remained stable (Figure 2). He was discharged with advice to avoid strenuous exercise and large carbohydrate portions, which may precipitate attacks of TPP [1]. He will be reviewed in a month to adjust the dosage of carbimazole, with an eventual aim for definitive therapy of Graves’ disease.

3. Discussion

This is the first case report of TPP occurring after COVID-19 infection, which presented with acute flaccid tetraparesis. Diagnosis can be a challenge as TPP can mimic neurological complications of COVID-19 infection such as Guillain-Barre syndrome. TPP is an uncommon complication of thyrotoxicosis, rarely affecting Caucasians, and patients tend to have mild clinical and biochemical features of hyperthyroidism, making the diagnosis more difficult [2].

3.1. Acute Flaccid Tetraparesis Associated with COVID-19 Infection. Multiple neurological complications following COVID-19 infection have been reported, including ischaemic stroke, intracranial haemorrhage, and acute encephalitis [3]. Though rare, cases of acute myelitis and demyelinating disorders (such as Guillain-Barre syndrome) have been reported, giving rise to acute tetraparesis [4]. Postulated mechanisms include direct viral invasion of the nervous system, cytokine storm, or molecular mimicry inducing an immune response [5]. Zuberebühler et al. conducted a review of 48 published cases of Guillain-Barre syndrome associated with COVID-19 infection, with neurologic manifestations occurring at mean of 12.1 days after the onset of COVID-19 symptoms [6]. Most patients (87.5%) required treatment with IV immunoglobulin therapy.

This patient’s presentation of acute tetraparesis and areflexia occurring ten days after COVID-19 infection was consistent with Guillain-Barre syndrome. However, it is imperative to exclude metabolic causes such as hypothycaemia or hypocalcaemia. Hypokalaemic and thyrotoxic periodic paralysis occur when there is an intracellular shift of potassium, leading to hyperpolarisation of cell membrane potential, and resultant flaccid paralysis and areflexia [2]. This can lead to the misdiagnosis of Guillain-Barre syndrome and emphasises the importance of obtaining results of serum electrolytes prior to instituting treatment such as immunoglobulin therapy [7].

In TPP, excess thyroid hormone mediates an increase in β-adrenergic receptor density and postreceptor mechanisms, which enhances tissue sensitivity to β-adrenergic stimulation [8]. This leads to increased sodium-potassium ATPase activity on skeletal muscles and an intracellular shift of potassium. Excess thyroid hormone also increases insulin response which in turn stimulates sodium-potassium ATPase activity [9]. TPP is a rare complication of thyrotoxicosis, with an incidence of 0.1% [10]. It is more common in Asian populations (incidence of up to 2%), and this may be due to a genetic predisposition or altered sodium-potassium channel mechanisms [11]. Like in our patient, it is most often observed in young males between 20 and 40 years of age [2].

There have not been any reported cases of TPP in association with COVID-19 infection thus far. Rajesh et al. reported a case of a 34-year-old male with COVID-19 infection who presented with hypokalaemic periodic paralysis [12]. The pathophysiology of hypokalaemic periodic paralysis appears to be similar to TPP, with shifts of potassium intracellularly being the main culprit. Association between COVID-19 and thyroiditis has been reported [13], postulated to be related to angiotensin-converting enzyme 2 (ACE-2), the receptor for cellular entry of the COVID-19 virus [14]. The mRNA encoding for the ACE-2 receptor has been found to be expressed in thyroid follicular cells, making them susceptible to viral entry, which may then give rise to thyroiditis [14]. COVID-19 infection is also known to be a trigger for various autoimmune and inflammatory diseases, mainly via molecular mimicry [15], and cases of Graves’ disease occurring after COVID-19 infection have been reported [16, 17]. It is postulated that COVID-19 infection may trigger Graves’ disease by altering the immune system in susceptible individuals [18]. Although this patient had a history of mild weight loss that preceded his COVID-19 infection, this had not been associated with any other
symptoms of thyrotoxicosis, and the onset of paralysis occurred only after the COVID-19 infection.

Thus, this patient’s recent COVID-19 infection may have exacerbated his hyperthyroidism, with his gender, age, and ethnicity making him particularly susceptible to developing TPP.

3.2. Treatment of Thyrotoxic Periodic Paralysis. Immediate treatment of TPP is necessary to reverse paralysis and prevent cardiopulmonary complications. For treatment of thyrotoxicosis, β-blocker therapy is vital in the acute phase, as it inhibits β-agonist stimulation and prevents intracellular shift of potassium [1]. This acts as a temporising measure till euthyroidism is achieved. Antithyroid drugs aid to control hyperthyroidism, but ultimately, these patients should be offered definitive therapy to eliminate the risk of subsequent paralysis attacks [2].

Management of severe hypokalaemia in these patients can be challenging. These patients are at risk of respiratory muscle paralysis, and fatal arrhythmias have occurred in cases of treatment delay [19–21]. Hence, immediate potassium replacement must be instituted. At the same time, caution must be exercised to avoid large quantities of potassium. Hypokalaemia in TPP is due to transcellular shift and not a total body deficit from renal or gastrointestinal losses, and reversal of the transcellular shift may lead to rebound hyperkalaemia. Hence, serum potassium levels must be monitored closely throughout replacement. Our case illustrated the difficulty in predicting the degree and rapidity of response to KCl replacement and β-blocker therapy. Despite propranolol and carbimazole therapy, as well as 90 mmol of KCl, patient’s potassium level remained extremely low at 2.2 mmol/L with persistent severe paralysis of all limbs. However, a further 40 mmol of KCl replacement

| Test                        | Result   | Reference |
|-----------------------------|----------|-----------|
| Urea                        | 6.1 mmol/L | 2.8–7.7  |
| Sodium                      | 141 mmol/L | 135–145  |
| Potassium                   | 1.7 mmol/L | 3.5–5.3  |
| Chloride                    | 106 mmol/L | 96–108   |
| Glucose                     | 6.2 mmol/L |           |
| Creatinine                  | 43 mmol/L  | 65–125    |
| Magnesium                   | 0.69 mmol/L | 0.65–0.95 |
| Calcium                     | 2.36 mmol/L | 2.1–2.6   |
| Phosphate                   | 0.57 mmol/L | 0.65–1.65 |
| FT4                         | 28.96 pmol/L | 10–20    |
| TSH                         | <0.004 pmol/L | 0.4–4    |
| FT3                         | 17.74 pmol/L | 2.5–5    |
| TSH receptor antibody       | 2.4 U/L     | <2        |
| Haemoglobin                 | 14.4 g/dL   | 13–17     |
| White blood cells           | 13.5 ×10^3/μL | 4–10      |
| Platelets                   | 310 ×10^3/μL | 150–450   |
| Bilirubin                   | 13.4 U/L    | 5–30      |
| Alkaline phosphatase        | 114 U/L     | 32–103    |
| Gamma-glutamyl transferase  | 37 U/L      | 5–50      |
| Alanine transaminase        | 41 U/L      | 10–55     |
| Aspartate transaminase      | 24 U/L      | 10–45     |
resulted in a rapid rise of serum potassium levels to 6.3 mmol/L.

A case-controlled study conducted by Lu et al. demonstrated that recovery time was significantly shorter in subjects with TPP who received IV KCl administration (10 mmol/h) compared to those who did not (6.3 ± 3.8 h vs. 13.5 ± 7.5 h) [22]. However, rebound hyperkalaemia (>5.5 mmol/L) occurred in 40% of patients who received IV KCl. Another case series of 24 patients with TPP conducted by Manoukian et al. reported that rebound hyperkalaemia (>5.0 mmol/L) occurred in 40%, especially if more than 90 mEq of KCl was given within 24 hours [23]. Thus, while KCl replacement does hasten recovery in patients with TPP, especially in those with risk of cardiopulmonary compromise, judicious amounts should be used (<10 mmol/h or <90 mmol/24h), with continuous telemetry and close monitoring for rebound hyperkalaemia [22, 23].

4. Conclusion and Learning Points

COVID-19 infection has been described to trigger a myriad of complications, including various autoimmune disorders. In a patient presenting with acute flaccid paralysis following COVID-19 infection, both neurological (e.g., acute myelitis, demyelinating conditions) as well as metabolic (electrolyte disturbances and hypokalaemia) disorders should be considered. Although TPP is a rare entity, a thyroid panel should be checked in COVID-19 patients with severe hypokalaemia, bearing in mind the association between COVID-19 and Graves’ disease. Last, the acute management of patients with TPP and severe hypokalaemia can be challenging, and judicious KCl replacement with frequent monitoring is imperative to avoid rebound hyperkalaemia.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Consent

Written consent was obtained from the patient for this case report.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] S.-H. Lin, “Thyrotoxic periodic paralysis,” Mayo Clinic Proceedings, vol. 80, no. 1, pp. 99–105, 2005.
[2] A. W. C. Kung, “Thyrotoxic periodic paralysis: a diagnostic challenge,” Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 7, pp. 2490–2495, 2006.
[3] A. Varatharaj, N. Thomas, M. A. Ellul et al., “Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study,” The Lancet Psychiatry, vol. 7, no. 10, pp. 875–882, 2020.
[4] E. C. Schulte, L. Hauer, A. B. Kunz, and J. Sellner, “Systematic review of cases of acute myelitis in individuals with COVID-19,” European Journal of Neurology, vol. 28, no. 10, pp. 3230–3244, 2021.
[5] A. Al-Ramadan, O. Rabab’h, J. Shah, and A. Gharibeh, “Acute and post-acute neurological complications of COVID-19,” Neurology International, vol. 13, no. 1, pp. 102–119, 2021.
[6] P. Zuberdübler, M. E. Conti, L. León Cejas et al., “Guillain-Barré syndrome associated to COVID-19 infection: a review of published case reports,” Revista de Neurología, vol. 72, no. 06, p. 203, 2021.
[7] R. Garg, H. Malhotra, R. Verma, P. Sharma, and M. Singh, “Etiological spectrum of hypokalemic paralysis: a retrospective analysis of 29 patients,” Annals of Indian Academy of Neurology, vol. 16, no. 3, p. 365, 2013.
[8] L. T. Williams, R. J. Lefkowitz, A. M. Watanabe, D. R. Hathaway, and H. R. Besch, “Thyroid hormone regulation of beta-adrenergic receptor number,” Journal of Biological Chemistry, vol. 252, no. 8, pp. 2787–2789, 1977.
[9] S. Soonthornpun, W. Setasuban, and A. Thamprasit, “Insulin resistance in subjects with a history of thyrotoxic periodic
paralysis (TPP),” *Clinical Endocrinology*, vol. 70, no. 5, pp. 794–797, 2009.

[10] K. P. Ober, “Thyrotoxic periodic paralysis in the United States report of 7 cases and review of the literature,” *Medicine (Baltimore)*, vol. 71, no. 3, pp. 109–120, 1992.

[11] A. J. McFadzean and R. Yeung, “Periodic paralysis complicating thyrotoxicosis in Chinese,” *BMJ*, vol. 1, no. 5538, pp. 451–455, 1967.

[12] J. Augustine, V. Rajesh, R. Divya, and M. Cleetus, “COVID-19 presenting as acute transient flaccid limb paralysis,” *Journal of Family Medicine and Primary Care*, vol. 10, no. 4, p. 1789, 2021.

[13] S. A. M. Mattar, S. J. Q. Koh, S. Rama Chandran, and B. P. Z. Cherng, “Subacute thyroiditis associated with COVID-19,” *BMJ Case Reports*, vol. 13, no. 8, Article ID e237336, 2020.

[14] M. Rotondi, F. Coperchini, G. Ricci et al., “Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis,” *Journal of Endocrinological Investigation*, vol. 44, no. 5, pp. 1085–1090, 2021.

[15] Y. Liu, A. H. Sawalha, and Q. Lu, “COVID-19 and autoimmune diseases,” *Current Opinion in Rheumatology*, vol. 33, no. 2, pp. 155–162, 2021.

[16] M. Mateu-Salat, E. Urgell, and A. Chico, “SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19,” *Journal of Endocrinological Investigation*, vol. 43, no. 10, pp. 1527–1528, 2020.

[17] K. Feghali, J. Atallah, and C. Norman, “Manifestations of thyroid disease post COVID-19 illness: report of Hashimoto thyroiditis, Graves’ disease, and subacute thyroiditis,” *Journal of Clinical and Translational Endocrinology: Case Reports*, vol. 22, Article ID 100094, 2021.

[18] L. H. Duntas and J. Jonklaas, “COVID-19 and thyroid diseases: a bidirectional impact,” *Journal of the Endocrine Society*, vol. 5, no. 8, Article ID bvab076, 2021.

[19] D. Y. Chen, P. F. Schneider, X. S. Zhang, Z. M. He, and T. H. Chen, “Fatal hypokalemic thyrotoxic periodic paralysis due to profound hypokalemia resulting from intravenous glucose administration and inadequate potassium replacement,” *Thyroid*, vol. 22, no. 9, pp. 969–972, 2012.

[20] B. B. Randall, “Fatal hypokalemic thyrotoxic periodic paralysis presenting as the sudden, unexplained death of a Cambodian refugee,” *The American Journal of Forensic Medicine and Pathology*, vol. 13, no. 3, pp. 204–206, 1992.

[21] J. Fisher, “Thyrotoxic periodic paralysis with ventricular fibrillation,” *Archives of Internal Medicine*, vol. 142, no. 7, pp. 1362–1364, 1982.

[22] K.-C. Lu, Y.-J. Hsu, J.-S. Chiu, Y.-D. Hsu, and S.-H. Lin, “Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis,” *The American Journal of Emergency Medicine*, vol. 22, no. 7, pp. 544–547, 2004.

[23] M. A. Manoukian, J. A. Foote, and L. M. Crapo, “Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes,” *Archives of Internal Medicine*, vol. 159, no. 6, p. 601, 1999.